Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar SkepBioInvestor (95.00) Submitted: 10/9/2012 4:16:00 PM : Underperform Start Price: $11.15 AMRN Score: +68.76

No NCE, sorry guys

Featured Broker Partners


Advertisement